ArticleIJU case reports2025
A case of testicular dysgenesis syndrome with squamous cell carcinoma of the prostate harboring a CDK12 mutation.
Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Penile metastasis from prostate cancer with CDK12 mutation: A case report and literature review.Oncology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary squamous cell carcinoma of the prostate is rare, and genetic profiling of this disease has not been established yet. Case presentation: We present a case of primary squamous cell carcinoma in a patient with testicular dysgenesis syndrome. The patient was diagnosed with prostate squamous cell carcinoma following intractable dysuria, and his serum prostate-specific antigen level was low. The patient had multiple lymph node and lung metastases, which led to administration of platinum-based chemotherapy. Additionally, targeted next-generation genome sequencing was performed to detect CDK12 mutations. Conclusion: Early imaging studies should be considered, even if the patient's prostate-specific antigen level is low when dysuria persists despite medical treatment. To the best of our knowledge, this is the first reported case of primary squamous cell carcinoma with a CDK12 mutation in a patient with TDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.